Indus Towers' share price continued its upward trajectory for the second consecutive day, rising nearly 1% on Thursday, following a 1.78% increase on Wednesday. The surge comes after Citi elevated Indus Towers to its top telecom pick, citing positive growth prospects and strategic acquisitions.
Citi's report highlighted that Indus Towers has received shareholder approval for the acquisition of 16,100 towers from Bharti Airtel and Hexacom for up to Rs 3,300 crore. This acquisition is expected to be earnings accretive, leading to a 3-5% increase in the company's FY26-27 Ebitda and a 1-2% rise in EPS forecasts.
Citi forecasts a core Ebitda compound annual growth rate of 10% for Indus Towers from FY25 to FY27, driven by an 8% tenancy CAGR. The brokerage also noted the stock's attractive dividend yield of 5-7%, making it a compelling investment opportunity.
Key catalysts for Indus Towers' growth include the resumption of dividend payouts, potential government relief for telecom operators, and improvements in Vodafone Idea's operating performance and debt raise completion. Citi has retained its 'buy' rating on Indus Towers with a lower target price of Rs 470.
Also Read: Bharti Airtel, Vodafone, Indus Towers Shares Fall After TRAI Data, Jio Deal With Starlink
The scrip rose as much as 0.83% to Rs 342 apiece. It pared gains to trade 0.34% higher at Rs 340 apiece, as of 09:27 a.m. This compares to a 0.56% advance in the NSE Nifty 50 Index.
It has risen 35.80% in the last 12 months. The relative strength index was at 52.
Out of 24 analysts tracking the company, 13 maintain a 'buy' rating, six recommend a 'hold,' and five suggest 'sell,' according to Bloomberg data. The average 12-month consensus price target implies an upside of 21.7%
RECOMMENDED FOR YOU

Citi Slashes Targets Across IT Pack — Check Latest Prices For TCS, Coforge And More


Nykaa Q1 Review: Brokerages See Fashion Break-Even In Sight; Citi Raises Price Target


Torrent Pharma Share Price Hits Life High After Citi Hikes Price Target Post Q1 Results


Torrent Pharma Q1 Review: Citi Hikes Target Price — Here's Why
